Investors seem to think a 37% drop this week presents a good opportunity to buy the biotech stock.
News & Analysis: Inovio Pharmaceuticals
And one reason why it isn't.
Lingering disappointment over results announced on Tuesday and an FDA update are weighing on the stock.
The results for INO-4800 were positive, but it’s much too early to celebrate.
The biotech's "positive" results from an early-stage study weren't positive enough for investors.
After an unbelievable week, Investors want to know if these drugmakers have what it takes to keep climbing.
Despite amazing run-ups, these two biotech stocks are too risky to buy right now.
One analyst thinks the biotech's shares have come too far too fast.
Investors are piling into coronavirus stocks as COVID-19 cases surge.
As COVID-19 cases surge, investors bid up coronavirus vaccine and treatment stocks.